On the other hand, in acute and chronic myeloid leukaemia (AML and CML, respectively) and acute lymphoblastic leukaemia (ALL), total NEAT1 levels decrease in patients’ peripheral blood and bone marrow, and this was found to be an essential mediator of apoptosis induced by imatinib in BCR-ABL-expressing cells [75,77,78,79,80]. Here, NEAT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.